Are you above the legal age to view this content in your province/state?

Home / Industry News / FSD PHARMA ANNOUNCES THE FILING OF AN AMENDED ANNUAL MD&A FOR 2018

FSD PHARMA ANNOUNCES THE FILING OF AN AMENDED ANNUAL MD&A FOR 2018

FSD PHARMA ANNOUNCES THE FILING OF AN AMENDED ANNUAL MD&A FOR 2018

TORONTO, October 23, 2019 – FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company”) announces that an amended and restated management’s discussion and analysis for the year ended December 31, 2018 (the “Amended 2018 MD&A“) has been filed on SEDAR to better comply with National Instrument 51-102 – Continuous Disclosure Obligations. The Amended 2018 MD&A was prepared following a continuous disclosure review by the Ontario Securities Commission (“OSC”) of the Company’s disclosure record.

The Amended 2018 MD&A was filed to address comments received from OSC staff and in order to improve the Company’s disclosure. Specifically, the Amended 2018 MD&A has been revised:

  • to provide an analysis of factors that have caused period to period variances in key financial statement balances as well as a discussion of factors which have caused variances in both revenue and profit or loss over the Company’s recently completed fiscal quarters;
  • to provide a breakdown of applicable material components of certain expenses;
  • to clarify the disclosure on the status of the construction of the Company’s facility in Cobourg, Ontario, and to update the related risk factor;
  • to provide more comprehensive disclosure regarding the Company’s liquidity and capital resources
  • to identify those persons party to Related Party Transactions disclosed in the Amended MD&A; and
  • to remove content deemed promotional by the OSC.

The revisions relate only to the management’s discussion and analysis and no changes were made to the financial statements for the relevant period.

About FSD Pharma

FSD Pharma is focused on the research and development of novel cannabinoid-based treatments for several central nervous system disorders including chronic pain, fibromyalgia and irritable bowel syndrome, and on the development of the highest quality indoor grown, pharmaceutical-grade cannabis. The Company is licensed to cultivate cannabis in approximately 25,000 square feet of its facility.

FSD’s wholly-owned subsidiary, FV Pharma, is a licensed producer under the Cannabis Act and Regulations, having received its cultivation license on October 13, 2017 and its full Sale for Medical Purposes license on June 21, 2019. FV Pharma intends to cover all aspects of the cannabis industry, including cultivation, legal, processing, manufacturing, extracts and research and development.

 

Disclaimer

Investment Value Finders specializes in providing opinions and information on stocks to individuals who wish to receive them. Our reports are construed for information purposes solely and are distributed free of charge to individuals who wish to receive them.


Investment Value Finders does not promote, condone or advocate licit or illicit drug use. Investment Value Finders cannot be held responsible for materials or contests posted on its website pages, or pages to which we provide links, which promote, condone or advocate licit or illicit drug use or illegal activities.


DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE. We are not registered as a securities broker-dealer or an investment adviser. We are neither licensed nor qualified to provide investment advice.


Investment Value Finders occasionally receives direct compensation for hosting links (or other* advertisements) to third party content that may be subject to disclaimer pursuant to Section 17(b) of the Securities Act of 1933. For those instances where the link text contains company or stock-specific mention, we provide the following list of compensation received in order to ensure full disclosure and transparency.


Investment Value Finders is intended for those 21+ years of age only!

Check Also

Ottawa to form advisory committee after Canadians voice interest in ‘cannabis health products’

Ottawa to form advisory committee after Canadians voice interest in ‘cannabis health products’

This story originally appeared on The Growth Op. The results are in from more than …